乳腺癌HER2低表达范式的导航:新标准与未来展望
本文综述HER2低表达乳腺癌的当前认知,讨论其是否应视为独立亚型、如何在临床中实施以及定义可能如何演变。约半数乳腺癌存在HER2低表达,可用抗体药物偶联物T-DXd靶向并在转移性场景带来生存获益,但生物学作用、病理诊断和定义本身仍存挑战。
要点
- 约半数乳腺癌存在HER2低表达,可用T-DXd靶向并在转移性场景带来生存获益。
- 激素受体阳性和三阴性乳腺癌的治疗算法预计将在未来显著演变。
- HER2低表达的生物学角色、病理诊断及定义本身仍存多项挑战。
核心结论
- HER2低表达范式的确认预计将对乳腺肿瘤学产生重大影响。
- 激素受体阳性和三阴性乳腺癌的治疗算法预计在未来显著演变。
研究设计与样本
- 本文为综述,汇总HER2低表达乳腺癌的当前知识,讨论其是否应视为独立亚型、如何临床实施及定义如何演变。
主要发现
- 约半数乳腺癌存在HER2低表达。
- HER2低表达可用抗HER2抗体药物偶联物T-DXd靶向,在转移性场景带来相关生存获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- HER2低表达的生物学作用、病理诊断及HER2低表达定义本身仍存多项挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The confirmation of the HER2-low paradigm is expected to have a major impact in breast oncology. About half of all breast cancers harbor HER2-low expression, which can be targeted with the anti-HER2 antibody-drug conjugate trastuzumab deruxtecan (T-DXd), leading to a relevant survival benefit in the metastatic setting. Given this observation, treatment algorithms for both hormone receptor-positive and triple-negative breast cancer are expected to significantly evolve in the next future. Several challenges, however, remain in the interpretation of HER2-low expression related to its biological role, its pathologic diagnosis, and the definition itself of HER2-low. In this article, we recapitulate the current knowledge on HER2-low breast cancer, discussing whether it should be considered a distinct subtype, how it should be implemented in the clinic, and how its definition may evolve in the coming years with the evolution of our clinical and translational knowledge.
引用
- Tarantino P, Curigliano G, Tolaney SM, et al. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. Cancer Discov. 2022. PMID: 35856622. doi:10.1158/2159-8290.CD-22-0703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。